To main content

Measuring mRNA-LNPs

Abstract

LNPs are by far the predominant delivery vectors for therapeutic mRNA. Their quality, safety and efficacy are crucially dependent on the choice of lipids, and also the formulation parameters.
mRNA-LNPs are unusually complex drugs, both in terms of their non-covalent internal structure which affects loading and stability, mRNA as a fragile and very large API, but also with regards to the effective surface chemistry and its in vivo interactions. This places unique demands on analytical methods for their characterization and quality control.
In the current work, the selection, suitability and application of analytical methods – and their orthogonality and complementarity, as requested by regulatory authorities – is presented, based on comprehensive comparisons and interlaboratory studies we have performed. A tiered analytical approach is proposed, from the early screening by batch methods like dynamic light scattering (DLS) or nanoparticle tracking analysis (NTA) to more in-depth analyses with e.g. multi-detector field flow fractionation (MF-FFF), differential scanning calorimetry (DSC) and analytical ultracentrifugation (AUC). We show that the latter methods are crucial to discover more subtle differences in LNP quality that are important for biological activity.

Category

Lecture

Client

  • EC/H2020 / 825828

Language

English

Author(s)

Affiliation

  • SINTEF Industry / Biotechnology and Nanomedicine

Presented at

12th International mRNA Health Conference

Place

Boston

Date

12.11.2024 - 14.11.2024

Organizer

Interplan / CureVac SE

Year

2024

View this publication at Cristin